BiotechTube

TYRA-300

Phase 1/2Active
0 watching 0 views this week💤 Quiet
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Locally Advanced Urothelial Carcinoma

Conditions

Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma, Solid Tumor, Adult, Bladder Cancer, Non-muscle-invasive Bladder Cancer, FGFR3 Gene Mutation, FGFR3 Gene Alteration, Advanced Solid Tumor, Advanced Urothelial Carcinoma, Urinary Tract Cancer, Urinary Tract Tumor, Urinary Tract Carcinoma

Trial Timeline

Nov 22, 2022 → Jun 1, 2027

NCT ID
NCT05544552

About TYRA-300

TYRA-300 is a phase 1/2 stage product being developed by Tyra Biosciences for Locally Advanced Urothelial Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT05544552. Target conditions include Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor.

Hype Score Breakdown

Clinical
13
Activity
8
Company
5
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05544552Phase 1/2Active

Competing Products

20 competing products in Locally Advanced Urothelial Carcinoma

See all competitors
ProductCompanyStageHype Score
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
NBTXR3NanobiotixPhase 1/2
36
Tadalafil + GemcitabineEli LillyPhase 1
33
SPYK04Chugai PharmaceuticalPhase 1
33
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
33
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
77
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3
77
T-DXd + Durvalumab + Cisplatin + Carboplatin + Pemetrexed + Volrustomig + RilvegostomigDaiichi SankyoPhase 1
33
ASP2998 + Pembrolizumab + Enfortumab Vedotin + CarboplatinAstellas PharmaPhase 1/2
41
zolbetuximabAstellas PharmaPre-clinical
23
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
52
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
77
enfortumab vedotin (EV)Astellas PharmaPre-clinical
23
zolbetuximabAstellas PharmaPre-clinical
23
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
77
ASP3082Astellas PharmaPhase 2
52
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
77
ASP1948Astellas PharmaPhase 1
33
Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )Sun PharmaceuticalPhase 2
52

Other Products from Tyra Biosciences

TYRA-300 0.125 mg/kg + TYRA-300 0.25 mg/kg + TYRA-300 0.375 mg/kg + TYRA-300 0.50 mg/kgPhase 2
47
TYRA-300 60mg + TYRA-300 50mg + TYRA-300 Dose TBDPhase 2
47
Dabogratinib (TYRA-300) 60mg + Dabogratinib (TYRA-300) 80mg + Dabogratinib (TYRA-300) TBDPhase 2
47
TYRA-430Phase 1
28
Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles + Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cyclesPhase 1
28